Compare NNI & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NNI | APGE |
|---|---|---|
| Founded | 1978 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.7B |
| IPO Year | 2003 | 2023 |
| Metric | NNI | APGE |
|---|---|---|
| Price | $133.21 | $134.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | ★ $140.00 | $109.67 |
| AVG Volume (30 Days) | 103.1K | ★ 5.4M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.93% | N/A |
| EPS Growth | ★ 134.86 | N/A |
| EPS | ★ 1.97 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.28 | N/A |
| Revenue Next Year | $5.38 | N/A |
| P/E Ratio | $68.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $116.62 | $34.34 |
| 52 Week High | $144.38 | $134.32 |
| Indicator | NNI | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 52.20 | 80.82 |
| Support Level | $127.63 | $80.52 |
| Resistance Level | $133.41 | N/A |
| Average True Range (ATR) | 2.47 | 0.42 |
| MACD | -0.00 | -1.52 |
| Stochastic Oscillator | 47.08 | 94.01 |
Nelnet Inc is a United States based company engaged in these four reportable segments; Loan Servicing and Systems, which focuses on student and consumer loan origination services and servicing, loan origination and servicing-related technology solutions, and outsourcing business services; Education Technology Services and Payments segment provides education services, payment technology, and community management solutions for K-12 schools, institutions, churches, and businesses; Asset Generation and Management segment includes the acquisition and management of student and other loan assets; and Nelnet Bank focuses on the private education and unsecured consumer loan markets. Maximum revenue for the company is generated from its Asset Generation and Management.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.